Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?

Annals of surgical oncology - 1 Nov 2006

Suh Kwang Wook, Kim Joo Hyung, Kim Do Yoon, Kim Young Bae, Lee Chulho, Choi Sungho

Abstract excerpt

BACKGROUND: Combination chemotherapy using oxaliplatin, 5-fluorouracil and folinic acid (FOLFOX) is known to be effective in the treatment of metastatic colon cancer. Genes regulating the actions of 5-fluorouracil and oxaliplatin have been identified, but precisely which gene is dominant has not...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Fluorouracil
Share to Korea

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leucovorin

Share to Methylenetetrahydrofolate Reductase (NADPH2)

Share to Organoplatinum Compounds

Share to Survival Rate

Share to X-ray Repair Cross Complementing Protein 1

Source

Identifiers

PMID: 17009149
DOI: 10.1245/s10434-006-9112-y

Genes

MTHFR
XRCC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17009149-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?PMID 17009149Read ↗

Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patientsSemantic proximity Read ↗

Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.Semantic proximity Read ↗

XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis.Semantic proximity Read ↗

Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapySemantic proximity Read ↗

[The influence of XRCC1 gene polymorphism on the prognosis and safety of stage Ⅲ patients with colorectal cancer who received oxaliplatin based adjuvant chemotherapy].Semantic proximity Read ↗

MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer.Semantic proximity Read ↗

Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer.Semantic proximity Read ↗

XRCC1 gene polymorphism for prediction of response and prognosis in the multimodality therapy of patients with locally advanced rectal cancer.Semantic proximity Read ↗

Prediction of genetic polymorphisms of DNA repair genes XRCC1 and XRCC3 in the survival of colorectal cancer receiving chemotherapy in the Chinese population.Semantic proximity Read ↗

KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients.Semantic proximity Read ↗

MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.